-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ondansetron is a medication that is primarily used to treat nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery.
It is also used to prevent and treat nausea and vomiting caused by motion sickness, pregnancy, and other conditions.
The chemical name for ondansetron is 4-(2,3-dichlorophenyl)-N-(2,2,2-trichloroethyl)-1,2,3,4-tetrahydrocarbazole-1-propanamide, which can be abbreviated as OND.
Ondansetron was first synthesized in 1979 by a team of researchers at Glaxo Wellcome (now GlaxoSmithKline).
The researchers were looking for new medications that could treat nausea and vomiting.
They tested various compounds, and eventually, they discovered that OND had a high degree of selectivity for the serotonin 5-HT3 receptor.
This receptor is found in the brain and gut and plays a role in controlling nausea and vomiting.
After the discovery of OND, the researchers studied its effects in animal models and human volunteers.
They found that OND was effective in reducing nausea and vomiting in these models.
In 1982, OND was approved by the FDA for the treatment of nausea and vomiting caused by cancer chemotherapy.
It was later approved for other indications, including the prevention and treatment of nausea and vomiting associated with radiation therapy, surgery, and other conditions.
The chemical structure of OND consists of a phenyl ring that is substituted with two chlorine atoms.
This ring is attached to a propanamide side chain that contains three chlorine atoms.
OND acts as an antagonist at the 5-HT3 receptor, which results in the inhibition of the release of neurotransmitters that trigger nausea and vomiting.
Ondansetron is available in various formulations, including oral tablets, oral solution, intravenous solution, and suppositories.
It is usually taken orally or administered intravenously in a healthcare setting.
The recommended dose and frequency of administration depend on the indication and the individual patient.
Ondansetron is well-tolerated in most patients, but side effects can occur.
The most common side effects are diarrhea, constipation, and dizziness.
These side effects are generally mild and do not require medical intervention.
However, serious side effects can occur in some patients, such as serotonin syndrome, which is a potentially life-threatening condition that can occur when too much serotonin is released in the brain.
Serotonin syndrome can occur when ondansetron is used in combination with other medications that increase serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and monoamine oxidase inhibitors.
Therefore, it is important to use ondansetron carefully and monitor patients for signs of serotonin syndrome, such as confusion, agitation, hallucinations, and excessive sweating.
In conclusion, ondansetron is a medication that is used to treat and prevent nausea and vomiting associated with various conditions.
It works by blocking the action of the serotonin 5-HT3 receptor, which is involved in controlling nausea and vomiting.
Ondansetron is well-tolerated in most patients, but side effects can occur, and it should be used carefully in combination with other medications that increase serotonin levels.
Overall, ondansetron is an effective and useful medication for managing nausea and vomiting.